Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genome-wide pharmacogenetics of anti-drug antibody response to bococizumab highlights key residues in HLA DRB1 and DQB1.

Scientific reports - 11 Mar 2022

Chasman Daniel I, Hyde Craig L, Giulianini Franco, Danning Rebecca D, Wang Ellen Q, Hickling Timothy, Ridker Paul M, Loomis A Katrina

Abstract excerpt

In this largest to-date genetic analysis of anti-drug antibody (ADA) response to a therapeutic monoclonal antibody (MAb), genome-wide association was performed for five measures of ADA status among 8844 individuals randomized to bococizumab, which targets PCSK9 for LDL-C lowering and cardiovascular protection. Index associations prioritized specific amino acid substitutions at the DRB1 and DQB1 MHC class II genes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Antibody Formation

Share to Genome-Wide Association Study

Share to Haplotypes

Share to HLA-DRB1 Chains

Share to Pharmacogenetics

Share to Proprotein Convertase 9

Source

Open in PubMed Open full text

Identifiers

PMID: 35277540
DOI: 10.1038/s41598-022-07997-5
PMCID: PMC8917227

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome-wide pharmacogenetics of anti-drug antibody response to bococizumab highlights key residues in HLA DRB1 and DQB1.PMID 35277540Read ↗

Relationship between HLA genetic variations, COVID-19 vaccine antibody response, and risk of breakthrough outcomes.Semantic proximity Read ↗

Establishing the Molecular Diagnoses in a Cohort of 291 Patients With Predominantly Antibody Deficiency by Targeted Next-Generation Sequencing: Experience From a Monocentric Study.Semantic proximity Read ↗

HLA-DQA1*05 is associated with the development of antibodies to anti-TNF therapySemantic proximity Read ↗

Impact of Human Genetic Variation Underlying Resistance to Antigen-Specific ImmunotherapySemantic proximity Read ↗

Sequence variants influencing the regulation of serum IgG subclass levels.Semantic proximity Read ↗

Allelic variation in HLA-DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro.Semantic proximity Read ↗

HLA Class II Alleles DRB1*11:01 and DQB1*03:01 Unmask Immunogenetic Susceptibility to Anti-Nivolumab Antibodies in Combination with Ipilimumab.Semantic proximity Read ↗

Treatment- and population-specific genetic risk factors for anti-drug antibodies against interferon-betaSemantic proximity Read ↗

Genetic polymorphisms of FcGR2B and adalimumab effectiveness in Colombian patients with rheumatoid arthritis. Cases-controls studySemantic proximity Read ↗

Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study.Semantic proximity Read ↗

Allelic Variation in<i>HLA-DRB1</i>is Associated with Development of Anti-Drug Antibodies in Cancer Patients Treated with Atezolizumab that are Neutralizing<i>in Vitro</i>Semantic proximity Read ↗

Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.